Limits...
Impact of comorbidities and use of common medications on cancer and non-cancer specific survival in esophageal carcinoma.

He LR, Qiao W, Liao ZX, Komaki R, Ho L, Hofstetter WL, Lin SH - BMC Cancer (2015)

Bottom Line: Seven kinds of frequently occurring chronic comorbidities and 18 types of regularly-taken medications were obtained from medical records.Overall mortality, EC-specific mortality and non EC-specific mortality were endpoints.Comorbidity information may better guide individual treatment in EC.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Cancer Center, Sun Yat-Sun University, Guangzhou, China, helir@sysucc.org.cn.

ABSTRACT

Background: Chronic comorbidities and some of the commonly-used medications are thought to affect cancer patients' outcomes, but their relative impact on esophageal carcinoma (EC) has not been well studied. The purpose of the study was to identify the chronic comorbidities and/or commonly-used medications that impact EC patient survival.

Methods: A total of 1174 EC patients treated with chemoradiotherapy (CRT) with or without surgery in one institution from 1998 to 2012 were retrospectively included. Seven kinds of frequently occurring chronic comorbidities and 18 types of regularly-taken medications were obtained from medical records. Since it is expected prognostic factors have different effects between surgery patients and non-surgery patients, the impact value of all variables and the corresponding interactions with surgery on survival were evaluated in Cox proportional hazards regression model. Overall mortality, EC-specific mortality and non EC-specific mortality were endpoints.

Results: We found that atrial fibrillation was the only comorbidity that showed a significant impact on non-EC specific survival for all patients (HR 1.72, P = 0.03), whereas hypothyroidism was the only comorbidity that was evaluated as an independent predictive factor for overall survival (OS) (HR 0.59, P = 0.02) and EC-specific survival (HR 0.62, P = 0.05), but this association was seen only in the non-surgical patients. No other medications were found to have a significant impact for OS, EC-specific survival or non-EC specific survival in multivariable analysis.

Conclusions: Our data indicate that certain comorbidities rather than medication use affect EC-specific survival or non EC-specific survival in EC patients treated with CRT with or without surgery. Comorbidity information may better guide individual treatment in EC.

Show MeSH

Related in: MedlinePlus

Non-esophageal carcinoma specific survival for patients with and without atrial fibrillation.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4359440&req=5

Fig1: Non-esophageal carcinoma specific survival for patients with and without atrial fibrillation.

Mentions: The median follow-up for the whole cohort was 25 months (3 to 186 months) with a 5y-OS of 38%. Besides the comorbidities and medications, the impact value of age, sex, race, body mass index (BMI), heavy alcohol use history, smoke at diagnosis, second malignancy, Karnofsky performance scores, tumor histology, tumor location, tumor differentiation, clinical stage, induction chemotherapy, radiation modality and their interactions with surgery were all tested in univariate analysis. Other factors which showed a significant impact on OS, EC-specific survival or non-EC specific survival in univariate analysis were listed in the footnote of Table 2. All the parameters included in the multivariate analysis were listed in the footnote of Table 3. After adjusting for patients’ baseline characteristics, AF was the only comorbidity that showed a significant impact on non-EC specific survival in both univariable (Table 2, Figure 1) and multivariable analysis (Table 3). For OS and EC-specific survival, hypothyroidism/levothyroxine was also the only significant factor in both univariable and multivariable analysis, with a significant interaction with surgery. It had a significant impact on OS (HR 0.59, 95% CI 0.38–0.93, P = 0.02) and EC-specific survival (HR 0.62, 95% CI 0.38–1.01, P = 0.05) for non-surgery patients but not for the surgery patients.Table 3


Impact of comorbidities and use of common medications on cancer and non-cancer specific survival in esophageal carcinoma.

He LR, Qiao W, Liao ZX, Komaki R, Ho L, Hofstetter WL, Lin SH - BMC Cancer (2015)

Non-esophageal carcinoma specific survival for patients with and without atrial fibrillation.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4359440&req=5

Fig1: Non-esophageal carcinoma specific survival for patients with and without atrial fibrillation.
Mentions: The median follow-up for the whole cohort was 25 months (3 to 186 months) with a 5y-OS of 38%. Besides the comorbidities and medications, the impact value of age, sex, race, body mass index (BMI), heavy alcohol use history, smoke at diagnosis, second malignancy, Karnofsky performance scores, tumor histology, tumor location, tumor differentiation, clinical stage, induction chemotherapy, radiation modality and their interactions with surgery were all tested in univariate analysis. Other factors which showed a significant impact on OS, EC-specific survival or non-EC specific survival in univariate analysis were listed in the footnote of Table 2. All the parameters included in the multivariate analysis were listed in the footnote of Table 3. After adjusting for patients’ baseline characteristics, AF was the only comorbidity that showed a significant impact on non-EC specific survival in both univariable (Table 2, Figure 1) and multivariable analysis (Table 3). For OS and EC-specific survival, hypothyroidism/levothyroxine was also the only significant factor in both univariable and multivariable analysis, with a significant interaction with surgery. It had a significant impact on OS (HR 0.59, 95% CI 0.38–0.93, P = 0.02) and EC-specific survival (HR 0.62, 95% CI 0.38–1.01, P = 0.05) for non-surgery patients but not for the surgery patients.Table 3

Bottom Line: Seven kinds of frequently occurring chronic comorbidities and 18 types of regularly-taken medications were obtained from medical records.Overall mortality, EC-specific mortality and non EC-specific mortality were endpoints.Comorbidity information may better guide individual treatment in EC.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiation Oncology, Cancer Center, Sun Yat-Sun University, Guangzhou, China, helir@sysucc.org.cn.

ABSTRACT

Background: Chronic comorbidities and some of the commonly-used medications are thought to affect cancer patients' outcomes, but their relative impact on esophageal carcinoma (EC) has not been well studied. The purpose of the study was to identify the chronic comorbidities and/or commonly-used medications that impact EC patient survival.

Methods: A total of 1174 EC patients treated with chemoradiotherapy (CRT) with or without surgery in one institution from 1998 to 2012 were retrospectively included. Seven kinds of frequently occurring chronic comorbidities and 18 types of regularly-taken medications were obtained from medical records. Since it is expected prognostic factors have different effects between surgery patients and non-surgery patients, the impact value of all variables and the corresponding interactions with surgery on survival were evaluated in Cox proportional hazards regression model. Overall mortality, EC-specific mortality and non EC-specific mortality were endpoints.

Results: We found that atrial fibrillation was the only comorbidity that showed a significant impact on non-EC specific survival for all patients (HR 1.72, P = 0.03), whereas hypothyroidism was the only comorbidity that was evaluated as an independent predictive factor for overall survival (OS) (HR 0.59, P = 0.02) and EC-specific survival (HR 0.62, P = 0.05), but this association was seen only in the non-surgical patients. No other medications were found to have a significant impact for OS, EC-specific survival or non-EC specific survival in multivariable analysis.

Conclusions: Our data indicate that certain comorbidities rather than medication use affect EC-specific survival or non EC-specific survival in EC patients treated with CRT with or without surgery. Comorbidity information may better guide individual treatment in EC.

Show MeSH
Related in: MedlinePlus